Toxicity of Synthetic Cannabinoids in K2/Spice: A Systematic Review
Open accessThe DOI matches its Crossref record; 99 of the 99 references it cites were found in a registry or an index.
Abstract
(1) Background: Synthetic cannabinoids (SCs) are emerging drugs of abuse sold as ‘K2’, ‘K9’ or ‘Spice’. Evidence shows that using SCs products leads to greater health risks than cannabis. They have been associated with greater toxicity and higher addiction potential unrelated to the primary psychoactive component of marijuana, Δ9-tetrahydrocannabinol (Δ9-THC). Moreover, early cases of intoxication and death related to SCs highlight the inherent danger that may accompany the use of these substances. However, there is limited knowledge of the toxicology of Spice ingredients. This systematic review intends to analyze the toxicity of SCs compounds in Spice/K2 drugs. (2) Methods: Studies analyzing synthetic cannabinoid toxicity and dependence were included in the present review. We searched the PubMed database of the US National Library of Medicine, Google Scholar, CompTox Chemicals, and Web of Science up to May 2022. (3) Results: Sixty-four articles reporting the effects of synthetic cannabinoids in humans were included in our review. Ten original papers and fifty-four case studies were also included. Fourteen studies reported death associated with synthetic cannabinoid use, with AB-CHMINACA and MDMB-CHMICA being the main reported SCs. Tachycardia and seizures were the most common toxicity symptoms. The prevalence of neuropsychiatric symptoms was higher in third-generation SCs. (4) Conclusion: SCs may exhibit higher toxicity than THC and longer-lasting effects. Their use may be harmful, especially in people with epilepsy and schizophrenia, because of the increased risk of the precipitation of psychiatric and neurologic disorders. Compared to other drugs, SCs have a higher potential to trigger a convulsive crisis, a decline in consciousness, and hemodynamic changes. Therefore, it is crucial to clarify their potential harms and increase the availability of toxicology data in both clinical and research settings.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The presence of synthetic cannabinoids and synthetic opioids like fentanyl indicates a global trend of increasing synthetic substance use [60].”
From Prevalence and patterns of substance use in West Africa: A systematic review and meta-analysis (2024) · cites this paper as [60]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Diagnostic and Statistical Manual of Mental Disorders
American Psychiatric Association (2013) · doi:10.1176/appi.books.9780890425596 · Cited by 116,369
Reprint—Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement
Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & and the PRISMA Group (2009) · Physical Therapy · doi:10.1093/ptj/89.9.873 · Cited by 2,486 · cited 1×
“The present review followed the PRISMA statement for transparent reporting of systematic reviews and meta-analyses [22], as presented in Figure 1.”
MethodSynthetic cannabinoids: Epidemiology, pharmacodynamics, and clinical implications
Castaneto, M. S., Gorelick, D. A., Desrosiers, N. A., Hartman, R. L., Pirard, S., & Huestis, M. A. (2014) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2014.08.005 · Cited by 709 · cited 6×
“Respectively, compounds JWH-018, JWH-122, and JWH-210 are 5, 60, and 82 times stronger than receiver ∆9-tetrahydrocannabinol (∆9-THC) [10,11].”
BackgroundInfluentialHermanns‐Clausen, M., Kneisel, S., Szabo, B., & Auwärter, V. (2013) · Addiction · doi:10.1111/j.1360-0443.2012.04078.x · Cited by 479
Beyond THC: The New Generation of Cannabinoid Designer Drugs
Fattore, L., & Fratta, W. (2011) · Frontiers in Behavioral Neuroscience · doi:10.3389/fnbeh.2011.00060 · Cited by 443
Cardiovascular effects of marijuana and synthetic cannabinoids: the good, the bad, and the ugly
Pacher, P., Steffens, S., Haskó, G., Schindler, T. H., & Kunos, G. (2018) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2017.130 · Cited by 439
Tait, R. J., Caldicott, D., Mountain, D., Hill, S. L., & Lenton, S. (2016) · Clinical Toxicology · doi:10.3109/15563650.2015.1110590 · Cited by 378
Synthetic Cannabinoid–Related Illnesses and Deaths
Trecki, J., Gerona, R. R., & Schwartz, M. D. (2015) · New England Journal of Medicine · doi:10.1056/nejmp1505328 · Cited by 331 · cited 1×
“The main objectives are safeguarding the airway, avoiding rhabdomyolysis, and monitoring for either cardiac or cerebral ischemia, in addition to administering intravenous fluids for dehydration [102,103].”
BackgroundSynthetic cannabinoid JWH-018 and psychosis: An explorative study
Every-Palmer, S. (2011) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2011.01.012 · Cited by 299
Spicing things up: synthetic cannabinoids
Spaderna, M., Addy, P. H., & D’Souza, D. C. (2013) · Psychopharmacology · doi:10.1007/s00213-013-3188-4 · Cited by 296 · cited 2×
“Respectively, compounds JWH-018, JWH-122, and JWH-210 are 5, 60, and 82 times stronger than receiver ∆9-tetrahydrocannabinol (∆9-THC) [10,11].”
Background
Research works printed but not linked: 1
- Roberts, 2015, Synthetic cannabinoids: Treating toxicity, Emerg. Med. News, 37, 12
Cited by
New Psychoactive Substances: Health and Legal Challenges
Santos, I. C. S., Maia, D., Dinis‐Oliveira, R. J., & Barbosa, D. J. (2024) · Psychoactives · doi:10.3390/psychoactives3020018 · Cited by 61
“However, the However, the long-term e ff ects of repeated use are poorly understood [39]. long-term effects of repeated use are poorly understood [39 Fatalities associated Fatalities associated with synthetic cannabinoids have been reported [40,41]. with synthetic cannabinoids have been reported…”
BackgroundNew Psychoactive Substances Toxicity: A Systematic Review of Acute and Chronic Psychiatric Effects
Taflaj, B., Maida, N. L., Tittarelli, R., Trana, A. D., & D’Acquarica, I. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25179484 · Cited by 38
“Similarly, stimulant NPSs were reported in only three cases, in which subjects with diagnosed schizophrenia showed increased aggressiveness and bizarre behavior [19,24].”
BackgroundSimon, G., Kuzma, M., Mayer, M., Petrus, K., & Tóth, D. (2023) · Toxics · doi:10.3390/toxics11080673 · Cited by 28
Prevalence and patterns of substance use in West Africa: A systematic review and meta-analysis
Emmanuel, G. O., Akinsolu, F. T., Abodunrin, O. R., & Ezechi, O. C. (2024) · PLOS Global Public Health · doi:10.1371/journal.pgph.0004019 · Cited by 24
Helander, A., Johansson, M., Villén, T., & Andersson, A. K. (2024) · Scandinavian Journal of Clinical and Laboratory Investigation · doi:10.1080/00365513.2024.2340039 · Cited by 16
Metadata
- Authors
- de Oliveira, M. C., Vides, M. C., Lassi, D. L. S., Torales, J., Ventriglio, A., Bombana, H. S., Leyton, V., Périco, C. D. A.-M., Negrão, A. B., Malbergier, A., & Castaldelli-Maia, J. M.
- Affiliations
- Interdisciplinary Group of Alcohol and Drug Studies (GREA), Institute Perdizes, Department of Psychiatry Medical School, São Paulo University, São Paulo 05403-903, SP, Brazil
- Universidade de São Paulo (BR)
- Universidad Nacional de Asunción (PY)
- University of Foggia (IT)
- Department of Neuroscience, Medical School, FMABC University Center, Santo André 09060-870, SP, Brazil
- ORCID
- Venue
- Brain Sciences
- Publisher
- MDPI AG
- Published
- 2023-06-24
- Volume
- 13
- Issue
- 7
- Pages
- 990
- ISSN
- 2076-3425 (ISSN-L)
- PMC
- PMC10377539
- OpenAlex
- W4382134818
- Semantic Scholar
- 26821b45771686aaf120d2ae692c64bed142c4e5
- Cited by
- 61
- References
- 99
- Citations by year
- 2026: 18 · 2025: 22 · 2024: 19 · 2023: 2
- FWCI
- 2.36
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Brain Sciences (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Forensic Toxicology and Drug Analysis
- Health Sciences › Medicine › Pharmacology (medical) › Cannabis and Cannabinoid Research
- Health Sciences › Medicine › Emergency Medicine › Poisoning and overdose treatments
- Keywords
- synthetic cannabinoids, drug toxicity, drug addiction, seizures, tachycardia, neuropsychiatric symptoms, convulsive crisis, drug-related deaths, epilepsy, schizophrenia, drugs of abuse
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Toxicity of Synthetic Cannabinoids in K2/Spice: A Systematic Review. https://app.cochat.ai/papers/10.3390/brainsci13070990
- The paper
- de Oliveira, M. C., Vides, M. C., Lassi, D. L. S., Torales, J., Ventriglio, A., Bombana, H. S., Leyton, V., Périco, C. D. A.-M., Negrão, A. B., Malbergier, A., & Castaldelli-Maia, J. M. (2023). Toxicity of Synthetic Cannabinoids in K2/Spice: A Systematic Review. Brain Sciences. https://doi.org/10.3390/brainsci13070990
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.